Xiaohong Zhou
Abstract
Increasing prevalence of respiratory diseases owing to the growing aging population and increasing pathogens in the environment has been the key factor driving the Chronic Obstructive Pulmonary Disease (COPD) market globally. Pharmaceutical companies have been developing new biobased medications in combination with bio-technology which promises immense growth opportunities along with sustainable development for COPD market over the next decade.